Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09

Journal of the National Cancer Institute

Volumn 86, Issue 12, 1994, Pages 906-912

  Schellens, Jan H M ^a   Planting, Andre S Th ^a   Van Acker, Bernadette A c ^b   Loos, Walter J ^a   Boer dennert, Maureen De ^a   Van Der Burg, Maria E l ^a   Koier, Ineke ^c   Krediet, Raymond T ^b   Stoter, Gerrit ^a   Verweij, Jaap ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Europ Org for Res and T   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; 5 (2 HYDROXYETHYLAMINO) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ALBUMIN; ALKYLATING AGENT; AMYLASE; ANTINEOPLASTIC AGENT; AZIRIDINE DERIVATIVE; CREATININE; CYTOTOXIC AGENT; DRUG METABOLITE; EO 5A; IMMUNOGLOBULIN G; INDOLOQUINOLINE DERIVATIVE; PANCREAS ENZYME; SODIUM; UNCLASSIFIED DRUG; WATER;

ACUTE KIDNEY FAILURE; ADENOCARCINOMA; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; EDEMA; EOSINOPHILIA; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; LEUKOPENIA; MALE; MAXIMUM PERMISSIBLE DOSE; MINIMAL CHANGE GLOMERULONEPHRITIS; NAUSEA; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PROTEINURIA; SALIVA; SODIUM RETENTION; SOLID TUMOR; VOMITING; WATER RETENTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AZIRIDINES; FEMALE; HUMANS; INDOLEQUINONES; INDOLES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROTEINURIA;

EID: 0028338822     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/86.12.906     Document Type: Article

References (23)

1. Hendriks HR, Pizao PE, Berger DP, et al: EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 29A:897–906, 1993
2. Oostveen EA, Speckamp WN: Mitomycin C analogues 1. Indoloquinones as potential bisalkylating agents. Tetrahedron 43:255–262, 1987
3. Walton MI, Suggett N, Workman P: The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys 22:643–647, 1992
4. Walton MI, Bibby MC, Double JA, et al: DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. Eur J Cancer 28A:1596–1600, 1992
5. Riley RJ, Workman P: DT-diaphorase and cancer chemotherapy. Biochem Pharmacol 43:1657–1669, 1992
6. Walton MI, Smith PJ, Workman P: The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun 7:199–206, 1991
7. Workman P, Stratford IJ: The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 12:73–82, 1993
8. Keyes SR, Fracasso PM, Heimbrook DC, et al: Role of NADPH: cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C. Cancer Res 44:5638–5643, 1984
9. Bailey SM, Friedlos F, Knox RJ, et al: Bioreductive activation of indoloquinone EO9: involvement of DT-diaphorase and DNA crosslinking. Ann Oncol 3 (suppl 1):186, 1992
10. Workman P: Bioreductive mechanisms. Int J Radiat Oncol Biol Phys 22:631–637, 1992
11. Adams GE, Stratford IJ, Edwards HS, et al: Bioreductive drugs on post-irradiation sensitizors: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9. Int J Radiat Oncol Biol Phys 22:717–720, 1992
12. Phillips RM, Hulbert PB, Bibby MC, et al: In vitro activity of the novel indoloquinone EO9 and the influence of pH on cytotoxicity. Br J Cancer 65:359–364, 1992
13. Workman P, Binger M, Kooistra KL: Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents. Int J Radiat Oncol Biol Phys 22:713–716, 1992
14. Bailey SM, Suggett N, Walton MI, et al: Structure-pharmacokinetic relationship for DT-diaphorase reduction of hypoxic cell directed agents. Indoloquinones and diaridinylbenzoquinones. Int J Radiat Oncol Biol Phys 22:649–653, 1992
15. Schellens JH, Loos WJ, Beijnen JH, et al: Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urine. J Chromatogr Biomed Appl 615:309–315, 1993
16. Holford NH, Sheiner LB: Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6:429–453, 1981
17. Cameron JS, Blandford G: The simple assessment of selectivity in heavy proteinuria. Lancet 2:242–247, 1966
18. Fox JG, Quin JD, O’Reilly DS, et al: Assessment of glomerular charge selectivity in man by differential clearance of isoamylases. Clin Sci 84:449–454, 1993
19. Bolton S: Pharmaceutical Statistics, Practical and Clinical Applications. New York: Marcel Dekker, 1985, pp 181-202
20. Anderson S, Diamond JR, Kamovsky MJ, et al: Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest 82:1757–1768, 1988
21. Schlager JJ, Powis G: Cytosolic NAD(P)H: (quinone-acceptor) oxido-reductase in human normal and tumor tissues: effects of cigarette smoking and alcohol. Int J Cancer 45:403–409, 1990
22. Lewis ED, Holyoake TL, Dunlop DJ, et al: Lack of myelosuppression with EO9 in human and mouse bone marrow: correlation with low DT-diaphorase. Proc Am Assoc Cancer Res 34:345, 1993
23. Verweij J, van der Burg ME, Pinedo HM: Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug. Radiother Oncol 8:33–41, 1987